J Rheum Dis.  2015 Feb;22(1):51-55. 10.4078/jrd.2015.22.1.51.

A Case of Essential Thrombocythemia in a Patient with Ankylosing Spondylitis Concomitantly Treated with Adalimumab

• Lee DS
• Lee SG
• Shin HJ
• Lee SH
• Park EK
• Na HJ
• Park CH
• Park JH
• Han IS
• Kim GT

• KMID: 2222928
• DOI: http://doi.org/10.4078/jrd.2015.22.1.51

Abstract

Extreme thrombocytosis in patients with ankylosing spondylitis (AS) is rarely reported. Because the relationship between high disease activity and increased platelet counts is somewhat contradictory, severe thrombocytosis in AS patients can be secondary to infection, iron deficiency anemia, drug administration, and hematologic malignancies. Essential thrombocythemia (ET) is a rare acquired stem cell neoplasm characterized by overproduction of platelets by megakaryocytes in the bone marrow in the absence of other causes of thrombocytosis. There is no report in the literature regarding the association between AS and ET. We report on a case of a 34-year-old Korean man with active AS diagnosed as JAK2V617F mutation negative ET during adalimumab treatment.

Keyword

Ankylosing spondylitis; Essential thrombocythemia; Tumor necrosis factor alpha

MeSH Terms

Adult
Anemia, Iron-Deficiency
Bone Marrow
Hematologic Neoplasms
Humans
Megakaryocytes
Platelet Count
Spondylitis, Ankylosing*
Stem Cells
Thrombocythemia, Essential*
Thrombocytosis
Tumor Necrosis Factor-alpha
Adalimumab
Tumor Necrosis Factor-alpha

Figure

• 

  Figure 1. Clinical course of the patient's platelet (PLT) count and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). BM: bone marrow.

• 

  Figure 2. Bone marrow biopsy in the patient shows hypercellular marrow (cellularity: 70%) with increased numbers of megakaryocytes with nuclear atypia such as hypolobulation (arrow in A), multinucleation (arrowhead in A) and grouping (cells ＜5, arrows in B) (H&E, ×400).

Reference

1. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Jt Bone Spine. 2008; 75:291–4.

2. Romero-Sánchez C, Robinson WH, Tomooka BH, Londoño J, Valle-Oñate R, Huang F, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol. 2008; 27:1429–35.

3. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets. 2010; 21:126–31.

4. Orüm H, Pamuk GE, Pamuk ON, Demir M, Turgut B. Does anti-TNF therapy cause any change in platelet activation in ankylosing spondylitis patients? A comparative study. J Thromb Thrombolysis. 2012; 33:154–9.

5. Ayvaz OC, Yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012; 32:269–71.

6. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22:14–22.

7. Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol. 2001; 115:320–2.

8. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013; 72:517–24.

9. Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012; 36:312–23.

10. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011; 29:573–82.

11. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013; 37:214–20.